GO:0004383 guanylate cyclase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0004383 guanylate cyclase activity is a molecular function defined as the catalysis of GTP conversion to 3',5'-cyclic GMP plus diphosphate.
• Guanylate cyclases exist as soluble heterodimers (sGC) and membrane-bound receptor enzymes, and their activity is essential for cGMP-mediated signaling in sperm, platelets, cardiac muscle, and liver [1,5,7,4].
• Soluble guanylate cyclase is a validated drug target; stimulators and activators are used to modulate cGMP production in cardiovascular and other diseases [2,8,6].
• Guanylate cyclase activity is regulated by nitric oxide, sodium azide, epidermal growth factor, and divalent cations such as Mg2+ [4,3,5].
• Dysregulated guanylate cyclase activity contributes to platelet dysfunction, cardiac disease, and male infertility, making it a focus for experimental models [5,7,1].
• CRISPR-based knockout, point mutation, knock-in, and overexpression models enable precise dissection of guanylate cyclase gene function in disease contexts [2,8].
Description
Guanylate cyclase activity (GO:0004383) is a fundamental enzymatic function that catalyzes the conversion of guanosine triphosphate (GTP) into 3',5'-cyclic guanosine monophosphate (cGMP) and diphosphate. This reaction is central to numerous physiological processes, including smooth muscle relaxation, platelet aggregation, sperm motility, and cardiac contractility [1,5,7]. The enzyme exists in two major forms: soluble guanylate cyclase (sGC), which is activated by nitric oxide, and membrane-bound receptor guanylate cyclases, which are stimulated by peptide ligands [2,8]. Because cGMP serves as a second messenger, the precise regulation of guanylate cyclase activity is critical for cellular homeostasis. Researchers study this term to understand signal transduction pathways, identify therapeutic targets, and model diseases such as hypertension, heart failure, and male infertility [2,8,1].
guanylate cyclase activity At A Glance
| GO ID | GO:0004383 |
|---|---|
| GO term | guanylate cyclase activity |
| Ontology | molecular_function |
| Synonym | GTP diphosphate-lyase (cyclizing; 3',5'-cyclic-GMP-forming) activity; guanyl cyclase activity; guanylyl cyclase activity; receptor guanylate cyclase activity |
| Major function | Catalysis of GTP to 3',5'-cyclic GMP and diphosphate |
| Reaction | GTP = 3',5'-cyclic GMP + diphosphate |
| Cofactors | Mg2+ or Mn2+ required for activity |
| Regulators | Nitric oxide, sodium azide, epidermal growth factor [4,3] |
| Localization | Soluble in cytosol; membrane-bound at sarcolemma and sarcoplasmic reticulum |
What Is GO:0004383?
Guanylate cyclase activity is the catalytic function that converts GTP into the cyclic nucleotide cGMP and diphosphate. This activity is performed by enzymes known as guanylate cyclases, which may be soluble or membrane-bound, and it represents a key step in cGMP-mediated signaling pathways.
Why Is guanylate cyclase activity Important in Cell Biology?
Guanylate cyclase activity is essential for cGMP signaling, which regulates diverse physiological functions including vascular tone, platelet aggregation, cardiac contractility, and sperm function [1,5,7]. Dysregulation of this activity is implicated in cardiovascular diseases, bleeding disorders, and infertility, and the enzyme is a major target for pharmacological stimulators and activators [2,8,6].
• Regulates smooth muscle relaxation and blood pressure through cGMP.
• Controls platelet aggregation and adhesion, impacting thrombosis and hemostasis.
• Essential for sperm motility and capacitation, affecting male fertility.
• Modulates cardiac contractility and is localized to sarcolemma and junctional sarcoplasmic reticulum.
• Targeted by sGC stimulators and activators for treating cardiovascular diseases [8,6].
• Activated by epidermal growth factor, linking growth factor signaling to cGMP.
• Requires divalent cations like Mg2+ for catalytic activity.
• Involved in liver function and azide-responsive signaling.
• Provides a therapeutic target for hypertension, heart failure, and pulmonary hypertension [2,8].
• Serves as a biomarker and research tool for cGMP-related pathways.
Mechanism, Genes and Research Methods
Substrate Binding and Catalysis
In simple terms: The enzyme grabs GTP and turns it into cGMP.
Guanylate cyclase binds GTP and catalyzes its cyclization to form 3',5'-cyclic GMP and diphosphate. This reaction requires divalent cations such as Mg2+ or Mn2+ for optimal activity. The catalytic mechanism involves the formation of a cyclic phosphodiester bond, releasing pyrophosphate.
Soluble vs. Receptor Guanylate Cyclases
In simple terms: There are two main types: one inside cells and one on the cell surface.
Soluble guanylate cyclase (sGC) is a heterodimeric enzyme activated by nitric oxide, while membrane-bound receptor guanylate cyclases are stimulated by extracellular peptide ligands [2,8]. Both forms catalyze the same reaction but differ in localization and regulation.
Regulation by Nitric Oxide and Other Factors
In simple terms: Nitric oxide and other molecules can turn the enzyme on or off.
Nitric oxide binds to the heme group of sGC, dramatically increasing its activity. Sodium azide also activates guanylate cyclase in rat liver. Epidermal growth factor enhances guanylate cyclase activity in vivo and in vitro. Platelet guanylate cyclase activity is influenced by various factors in lysates.
Cellular Localization and Compartmentalization
In simple terms: The enzyme is found in specific parts of the cell to do its job.
In cardiac muscle, guanylate cyclase activity is preferentially localized at the sarcolemma and junctional sarcoplasmic reticulum. This spatial organization allows for localized cGMP signaling.
Key Genes Involved in GO:0004383 guanylate cyclase activity
The following genes and proteins are key players in guanylate cyclase activity and cGMP signaling.
| Gene | Major Role | Research Relevance |
|---|---|---|
| GUCY1A3 | Alpha subunit of soluble guanylate cyclase | Target for sGC stimulators; cardiovascular disease |
| GUCY1B3 | Beta subunit of soluble guanylate cyclase | Heme-binding subunit; nitric oxide sensing |
| GUCY2C | Receptor guanylate cyclase in intestine | Role in fluid secretion and cancer |
| GUCY2D | Retinal guanylate cyclase | Phototransduction and retinal degeneration |
| GUCY2F | Retinal guanylate cyclase | Sperm function and vision |
| NPR1 | Receptor guanylate cyclase for ANP/BNP | Blood pressure regulation |
| NPR2 | Receptor guanylate cyclase for CNP | Skeletal development and oocyte maturation |
| NOS1 | Neuronal nitric oxide synthase | Produces NO to activate sGC |
| NOS2 | Inducible nitric oxide synthase | Inflammatory NO production |
| NOS3 | Endothelial nitric oxide synthase | Vascular NO production |
| PDE5 | cGMP-specific phosphodiesterase | Degrades cGMP; target for erectile dysfunction drugs |
| PRKG1 | cGMP-dependent protein kinase I | Mediates cGMP effects |
| PRKG2 | cGMP-dependent protein kinase II | Intestinal and bone signaling |
| CNGA1 | Cyclic nucleotide-gated channel | Phototransduction and sperm chemotaxis |
| CNGB1 | Cyclic nucleotide-gated channel | Retinal signaling |
| HSP90 | Chaperone for sGC maturation | Stabilizes sGC heterodimer |
| ATP1A1 | Sodium/potassium ATPase | Indirectly affects cGMP via ion balance |
How Is guanylate cyclase activity Regulated?
Guanylate cyclase activity is regulated at multiple levels. Soluble guanylate cyclase is activated by nitric oxide binding to its heme moiety, which induces a conformational change that increases catalytic rate. Sodium azide can also activate the enzyme in liver. Epidermal growth factor enhances guanylate cyclase activity, linking growth factor signaling to cGMP production. In platelets, activity is modulated by various factors present in lysates, including divalent cations. Pharmacological stimulators and activators of sGC can directly enhance its activity, and these agents are used to treat cardiovascular diseases [8,6].
guanylate cyclase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| GUCY1A3 | Hypertension, heart failure | Knockout mouse; point mutation of heme-binding site |
| GUCY1B3 | Cardiovascular disease | Knock-in of human mutations; sGC activator testing |
| GUCY2C | Colorectal cancer, diarrhea | Knockout and overexpression cell lines |
| NPR1 | Hypertension | Knockout rat; knock-in of human variants |
| PDE5 | Erectile dysfunction | Point mutation to alter cGMP binding |
Cardiovascular Disease
Impaired guanylate cyclase activity contributes to hypertension, heart failure, and pulmonary hypertension due to reduced cGMP-mediated vasodilation [2,8]. Soluble guanylate cyclase stimulators and activators are therapeutic strategies to restore cGMP signaling.
Platelet Disorders
Guanylate cyclase activity in platelets influences aggregation and thrombosis; dysregulation can lead to bleeding or thrombotic disorders.
Male Infertility
Guanylate cyclase activity is critical for sperm function, including motility and capacitation; altered activity is associated with male infertility.
Cardiac Hypertrophy
Localization of guanylate cyclase at sarcolemma and junctional sarcoplasmic reticulum suggests a role in cardiac contractility and hypertrophy.
From guanylate cyclase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of GUCY1A3 affect blood pressure? | Knockout mouse or rat |
| How do point mutations in GUCY1B3 alter NO sensitivity? | Point mutation knock-in cell lines |
| Can overexpression of GUCY2C rescue cGMP levels? | Overexpression stable cell lines |
| What is the role of sGC in platelets? | Platelet-specific knockout |
| How does EGF regulate guanylate cyclase? | Knock-in of EGF receptor mutants |
| Does sodium azide activation require specific residues? | Point mutation of catalytic domain |
How to Study the guanylate cyclase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Guanylate cyclase activity assay | Conversion of GTP to cGMP | Enzyme kinetics and drug screening |
| cGMP ELISA | Intracellular cGMP levels | Signaling pathway analysis |
| Cytochemistry | Enzyme localization | Tissue-specific expression |
| Western blot | Protein expression of sGC subunits | Knockout validation |
| CRISPR knockout | Gene function loss | Disease modeling |
| CRISPR knock-in | Point mutations or tags | Structure-function studies |
| RNA-seq | Transcriptional changes | Pathway analysis |
| Proteomics | Protein interactions | sGC complex composition |
Enzymatic Activity Assays
Guanylate cyclase activity is measured by incubating cell lysates with GTP and quantifying cGMP production using radioimmunoassay or ELISA [1,5]. This method directly assesses catalytic function.
cGMP Quantification
cGMP levels can be measured by immunoassays or mass spectrometry to infer guanylate cyclase activity in cells and tissues.
Histochemistry and Imaging
Cytochemical demonstration of guanylate cyclase activity allows visualization of its localization in tissues, such as cardiac muscle.
Genetic Knockout and Knock-in Models
CRISPR-Cas9 mediated knockout or knock-in of guanylate cyclase genes enables functional studies in cell lines and animal models [2,8].
How CRISPR Can Be Used to Study GO:0004383 guanylate cyclase activity
Knockout
CRISPR knockout of guanylate cyclase genes (e.g., GUCY1A3, GUCY1B3) abolishes enzyme activity, allowing researchers to study loss-of-function phenotypes in cardiovascular and platelet biology [2,8].
Point Mutation
Point mutations can be introduced into catalytic or regulatory domains to dissect the mechanism of GTP binding, heme coordination, or nitric oxide sensitivity [4,8].
Knock-in
Knock-in of disease-associated variants or epitope tags enables precise modeling of human mutations and protein localization studies [2,6].
Overexpression
Overexpression of guanylate cyclase genes in cell lines can enhance cGMP production and is used to study downstream signaling and drug responses [1,6].
How EDITGENE Supports guanylate cyclase activity Research
Researchers studying guanylate cyclase activity-related genes often need to determine whether a candidate gene is causally involved in cGMP signaling, disease progression, or drug response. EDITGENE provides comprehensive CRISPR services to generate precisely engineered cell models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for guanylate cyclase activity research.
Frequently Asked Questions About guanylate cyclase activity
What is guanylate cyclase activity?
Guanylate cyclase activity is the enzymatic function that converts GTP into 3',5'-cyclic GMP and diphosphate, a key step in cGMP signaling.
What genes are involved in guanylate cyclase activity?
Key genes include GUCY1A3, GUCY1B3, GUCY2C, GUCY2D, NPR1, and NPR2, which encode various guanylate cyclase enzymes [1,2].
What is the GO ID for guanylate cyclase activity?
The GO ID is GO:0004383.
How is guanylate cyclase activity regulated?
It is regulated by nitric oxide, sodium azide, epidermal growth factor, and divalent cations like Mg2+ [2,4,3].
What diseases are associated with guanylate cyclase activity?
Cardiovascular diseases, platelet disorders, and male infertility are linked to altered guanylate cyclase activity [2,5,1].
What are sGC stimulators and activators?
They are pharmacological agents that enhance soluble guanylate cyclase activity and are used to treat cardiovascular diseases [8,6].
How can I measure guanylate cyclase activity?
Activity is measured by incubating lysates with GTP and quantifying cGMP production via immunoassay or mass spectrometry [1,5].
What model systems are used to study guanylate cyclase activity?
Knockout mice, knock-in cell lines, and overexpression models are commonly used [2,8].
Is guanylate cyclase activity important for sperm function?
Yes, it is critical for sperm motility and capacitation, and its dysregulation is linked to male infertility.
Can CRISPR be used to study guanylate cyclase activity?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models enable precise functional studies [2,8].
Conclusion
Guanylate cyclase activity (GO:0004383) is a central enzymatic function in cGMP signaling, with critical roles in cardiovascular, platelet, and reproductive biology [1,2,5]. Its regulation by nitric oxide, growth factors, and cations makes it a versatile target for pharmacological intervention [3,4,6]. CRISPR-based models provide powerful tools to dissect its mechanisms and disease relevance, and EDITGENE offers comprehensive services to support such research.
References
- 1. Revelli A et al.. 2002. Guanylate cyclase activity and sperm function.. Endocr Rev 23(4):484-94 PMID: 12202462
- 2. Xiao S et al.. 2019. Soluble Guanylate Cyclase Stimulators and Activators: Where are We and Where to Go?. Mini Rev Med Chem 19(18):1544-1557 PMID: 31362687
- 3. Scheving LA et al.. 1985. Epidermal growth factor enhances guanylate cyclase activity in vivo and in vitro.. Endocrinology 116(1):332-6 PMID: 2856873
- 4. Kimura H et al.. 1976. Appearance of magnesium guanylate cyclase activity in rat liver with sodium azide activation.. J Biol Chem 251(24):7769-73 PMID: 12177
- 5. Adams AF et al.. 1978. Factors affecting the activity of guanylate cyclase in lysates of human blood platelets.. Biochem J 174(1):23-35 PMID: 29607
- 6. Petraina A et al.. 2025. Revisiting soluble guanylate cyclase pharmacology: Additive potential of stimulators and activators.. Biomed Pharmacother 193:118762 PMID: 41252787
- 7. Schulze W et al.. 1983. Cytochemical demonstration of guanylate cyclase activity in cardiac muscle. Preferential localization at sarcolemma and junctional sarcoplasmic reticulum.. Histochemistry 77(2):243-54 PMID: 6132898
- 8. Sandner P et al.. 2021. Soluble Guanylate Cyclase Stimulators and Activators.. Handb Exp Pharmacol 264:355-394 PMID: 30689085
